Abstract

---

The diagnosis of Henoch-Schonlein purpura (HSP) is difficult, especially when abdominal symptoms precede cutaneous lesions. We report three cases of adult HSP revealed by gastrointestinal (GI) involvement.

Introduction

---

Henoch Schonlein purpura (HSP) is a leucocytoclastic vasculitis involving small vessel with deposition of immune Ig A complexes. HSP primarily affects children, (approximately 15 cases/100.000 per year) (1).  It is less common among adults. Clinically, HSP is characterized by palpable purpura, arthritis, renal and gastrointestinal involvement.  Among adults,  the incidence of HSP, the clinical features and the severity seems to be different compared to children (2). Except for potential intestinal complications, its prognosis is usually excellent. However, nephritis is another complication that might have less prognosis. We report three cases of adult-onset HSP revealed by gastrointestinal (GI) involvements.

Review

---

Case reports:
Over a period of 2 years (2009-2010), three patients with adult-onset HSP were admitted to Department of Internal Medicine. The clinical profiles, along with laboratory and radiological data, of the three patients are shown in Table 1. GI involvements were the first symptoms in the 3 cases. Skin biopsy showed leucocytoclastic vasculitis with Ig A and C3 deposits in direct immunofluorescence (DIF). In the first case, the colonoscopy showed the presence of colic poliposis with moderate dysplasia on the biopsy. Tumor markers (ACE, AFP, PSA, Ca-19-9) were negative. The kidney biopsy revealed “Extracapillar glomerulonephritis with Ig A depositis in DIF) and the patients received 6 monthly cyclophosphamide pulse. Our second patient presented initially with acute appendicitis confirmed by the histological finding. There was no depositis in the DIF. All the patients had complete recovery from their abdominal symptoms within approximately three weeks.

Discussion

---

HSP usually presents with a classic tetrad of rash, polyarthralgias, abdominal pain and renal disease. The clinical presentation of HSP is more severe among adult and tends to be atypical: Higher rate of severe and atypical GI problems and delayed renal complications. (3)
Older patients showed much more severe renal and extra-renal manifestations than younger patients in which the joint manifestations appear to be the most frequent. However, the severe GI involvements are less common in adults than children. (4-5)
GI involvements occur in 50- 75% of adult patients. (6)
The mechanism of GI involvement in HSP may include IgA deposits on small vessel wall and polymorphonuclear neutrophils (PMNs) infiltration around vessels. (3)
In a recent retrospective study including 115 adults with the diagnosis of HSP, GI were found in 90 patients (78.2%). (7)
In a large Italian cohort of 250 patients, adults and children, with HSP, necrotic purpura was present in 96% of the cases, arthritis in 61% of the cases and GI involvement in 48% of cases. The main symptom was colicky abdominal pain. Bleeding occurred in 51% cases of GI involvement and was serious, requiring transfusion or surgery or leading to death in 11% of the cases. (8)
In the retrospective study conducted by Chang and all, including 261 children with a diagnosis of HSP, 151 (58%) had abdominal pain and 46 (17.6%) had GI bleeding detected as positive stool occult blood. Seven patients had gross bloody stools. (7)
When comparing 82 children and 20 adults with HSP, Uppal and all found that the frequency nausea, vomiting, malena/hematochezia and intussusception were the same in both groups. Adults had a higher frequency of diarrhea. (10)
When studying 46 adults and 116 children with HSP, Blanco and all reported a higher incidence of renal (p
In rare cases, GI involvements revealed HSP, as in our 3 patients. It was reported by Farah (12) and Moles (13). Al Toma and all described a case of a 40- year’s old man who presented with terminal ileitis complicated by thrombotic microangiopathy. (14)
GI was the first manifestation of HSP in 11% of the patients of Trappani (15) and 8% of those of Coppo. (8)
Another important retrospective study was performed by Chen and Kong including 161 patients; colicky abdominal pain was noticed in 98.1% and vomiting in 39.5% of the patients. In 25 (3%) of the reported cases, GI symptoms were manifested before skin rash. (16)
The classic findings may consist in: Periumbilical colicky and abdominal pain (related to edema, bleeding), nausea, vomiting, diarrhea, constipation, abdominal distension which are usually mils and rarely severe enough to be confused with an acute abdomen leading to laparotomy. Rare GI manifestations may include: Intestinal perforation, ischemic vasculitis, intussusceptions, esophageal ulcers, pancreatitis, pseudomembranous colitis, extensive GI bloodloss requires hemodynamic monitoring, transfusion and occasionally emergent surgical intervention, appendicitis, massive bowel necrosis. Massive GI hemorrhage and grossly bloody or melanotic stools are respectively reported in 2% and 30% of the patients. (17, 18, 19, 20)
Simultaneous occurrence HSP and acute appendicitis is rarely observed, like in our second case. (21).
Mucosal lesions develop anywhere within the GI tract. Diffuse mucosal redness, small ring-like petechiae and hemorrhagic erosions are characteristic endoscopic findings. The small intestine is considered to be the most frequently affected site. Duodenal involvement was more prominent in the second part of the duodenum than in the bulb. (22)
Imaging studies consisting in abdominal X –ray film, abdominal echography, and abdominal CT, and stool occult blood tests are important examinations (9). Laparotomy which is performed in approximately 10% is usually when esophagogastroduodenoscopy, colonoscopy and small bowel barium radiogram show normal results. Videocapsule endoscopy represents a unique improvement in the investigation of intestinal diseases, allowing an excellent visualization of the mucosa of the small bowel. (23)
Malignancy also has been reported as a rare causative factor of HSP (24). The recent retrospective study conducted by Mitsui and all found 53 cases of malignant tumors. (25). The first patient had colic dysplasia. No previous association has been reported so far.
Helicobacter pylori (Hp) infection may be associated with the development and relapse of HSP with gastrointestinal involvement among children; Wang found that 21 of 36 HSP patients with GI manifestations were confirmed with Hp infection (58.3%). Among those patients, the relapsed patients had a Hp positive rate of 81.3% (13/16), which was significantly higher than the newly diagnosed patients (45.0%, 9/20; P < 0.05). Two of our patients had Hp infection at the moment of the diagnosis. (26)
When studying 11 adult patients with HSP and 20 healthy subjects, Novak concluded that IgG antibodies to Hp may be present mostly in acute HSP, while IgA antibodies may be involved in sustaining gastrointestinal symptoms underlying the chronic phase of the disease. (27)
The cutaneous pathology of H. pylori is far from being clear, but it is speculated that the systemic effects may involve increased mucosal permeability to alimentary antigens, immunomodulation, an autoimmune mechanism or the impairment of vascular integrity. (28)
Recently, polymorphism at codon 469 of the intercellular adhesion molecule-1 (ICAM-1) locus has been associated with protection against severe gastrointestinal complications in HSP. (29)
In most cases, HSP spontaneously disapperas without treatment. The use of corticosteroids is controversial and usually reserved for severe systemic manifestations. (30)
Steroid treatment makes improvement in the GI symptoms at an early stage but does not prevent the recurrence of abdominal pain attacks. Steroids decrease the intestinal wall edema and thus the symptoms improve or disappear.
In A Randomized, Double-Blind, Placebo-Controlled Trial, including 171 patients with HSP, Prednisone was effective in reducing abdominal pain (p=0,028); the incidence of severe abdominal pain necessitating hospital admission was greater in the placebo group than in the prednisone group. (31). These data are in keeping with those of Peru and all; these authors conclude that the steroid treatment given to HSP patients with GI manifestations might be helpful to prevent probable complications such as bleeding and intussusceptions. (32)
The use of gastric acid secretion inhibitors are also very beneficial on GI involvement.

Conclusion(s)

---

GI involvements are frequent in HSP. The diagnosis is more difficult when they precede the other manifestations and especially the cutaneous rash. Treatments are still controversial.

References

---

1. Nielsen HE. Epidemiology of Schonlein-Henoch purpura. Acta Paediatr Scand 1988; 77: 125-131.
2. Shrama A, Wanshu A, Kalra N, Singh S, Bambery P. Successful treatement of severe gastrointestinal involvement in adult- onset Henoch Schonlein Purpura. Singapore Med J Case Report 2007; 48: 1047- 50.
3. Roberts PF, Waller TA, Brinker TM, Riffe IZ, Sayre J, Bratton RL. Henoch Schonlein purpura: A review article. Southern Med J 2007; 100: 821-24.
4. Blazquez MR, Charlier A, Bognel JC. Manifestations digestives sévères du PR de l’adulte. Ann Gastroenterol Hepatol 1994; 30: 5-8.
5. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein Purpura in Adults: Outcome and Prognostic Factors. J Am Soc Nephrol 2002; 13: 1271-1278.
6. Saulsbury FT. Cliniacal update: Henoch Schonlein purpura. Lancet 2007; 369: 976-78.
7. Zhang Y, Huang X. Gastrointestinal involvement in Henoch-Schönlein purpura.Scand J Gastroenterol 2008; 43: 1038-43.
8. Coppo R, Mazzucco G, Cagnoli L, Lupo An Schena FP. Long term prognosis of Henoch Schonlein nephritis in adult and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch Schonlein purpura. Nephrol Dial Transplant 1997; 12: 2277-2283.
9. Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch Schonlein purpura: a review of 261 patients. Acta Peadiatr 2004; 93: 1427-1431.
10. Uppal SS, Hussain MA, Al-Raqum HA, Namppry MR, Al- Saied K, Al Assousi A, Abraham M, Malaviva AN. Henoch Schönlein's purpura in adults versus children/adolescents: A comparative study. Clin Exp Rheumatol 2006; 24: S26-30.
11. Blanco R, Tobada Martinez VM, Garcia-Fuentes M, Gonzalez-Gay MA. Henoch Schonlein purpura in adulthood and children: Two different expressions of the same syndrome. Arthritis Rheum 1997; 40: 859-64
12.  Farah R, Shay M. Gastrointestinal involvement in Henoch Schonlein purpura. Minerva Gastroenterol Dietol 2007; 53: 295-99.
13. Moles JR, Del Val A, Morillas J, Gaspar E, Garrigues V, Berenguer J. Gastrointestinal involvement as the first manifestation of Schoenlein-Henoch purpura. Rev Esp Enferm Dig 1991; 79: 361-2.
14. Al Toma A, Brink MA, Hagen EC. Henoch-Schönlein purpura presenting as terminal ileitis and complicated by thrombotic microangiopathy. Eur J Int Med 2005; 16: 510-12.
15. Trapani S, Micheli A, Grisolia F, resti M, Chiappini E, Falcini F, Martino M. Henoch Schonlein Purpura in Childhood: Epidemiological and Clinical Analysis of 150 Cases Over a 5-year Period and Review of Literature. Semin Arthritis Rheumatol 2005; 35: 143-53.
16. Chen SY, Kong MS. Gastrointestinal manifestations and complications of Henoch Schonlein purpura. Chang Gung Med 2004; 27: 175-81.
17. Akbar DH. Fatal complication of Henoch Schonlein purpura: Case report and literature review. Saudi J Gastroenterol 2000; 6: 165-8.
18. Ebert EC. Gastrointestinal manifestations of Henoch-Schonlein Purpura. Dis Dig Sci 2008; 53: 2011-9.
19. Passam FH, Diamantis ID, Perisinaki G, Saridaki Z, Kritikos H, Georgopoulos D, Boumpas DT. Intestinal ischemia as the first manifestations of vasculitis. Semin Arthirtis Rheum 2004; 34: 431-441.
20. Degushi M, Shiraki K, Itoh N. Esophageal involvement in Schonlein Henoch purpura. Gastrointestinal Endoscopy 2001; 53: 241-44.
21. Jangjoo A, Amouzeshi A, Jalali AN. Gangrenous appendicitis in a child with Henoch-Schonlein purpura. Journal of Pediatric Surgery 2008; 43, E33- E35.
22. Esaki M, Takayuki M, shotaro N, Kawasaki M, Iwai K, Hirakawa K, Tarumi KI, Yao T, Lida M. GI involvement in Henoch-Schonlein purpura. Gastrointestinal Endoscopy 2002; 56: 920-23.
23. Stancanelli B, Vita A, Vinci M, Magnano A, Purrello F. Bleeding of small bowel in Henoch Schonlein syndrome: The successful diagnosis role of video capsule endoscopy. Am J Med 2006; 119: 82-90.
24. Zurada JM, Ward KM, Grossman EM. Henoch Schonlein purpura associated with malignancy in adults. J Am Acad Dermatol 2006; 55: S65-70
25. Mitsui H, Shibagaki N, Kawamura T, Matsue H, Shimada S. A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol 2009; 23: 394-401.
26. Wang BH, Zhou LQ, Zuo YH. Relationship between Helicobacter pylori infection and Henoch-Schonlein purpura with gastrointestinal involvement in children. Zhongguo Dang Dai Er Ke Za Zhi 2007; 9: 367-9.
27. Novák J, Szekanecz Z, Sebesi J, Takáts A, Demeter P, Bene L, Sipka S, Csiki Z.  Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schönlein purpura. Autoimmunity 2003; 36: 307-311.
28. Weddi B, Kappa A.  Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002; 4: 273- 282.
29. Amoli MM, Mattey DL, Calvino MC, Garcia-Porrua C, Thomson W, Hajeer AH, Ollier WE, Gonzales-Gay MA. Polymorphism at codon 469 of the intercellular adhesion molecule-1locus is associated with protection against severe gastrointestinal complications in Henoch-Schonlein purpura. J Rheumatol 2001; 28: 1014-8.
30. Yamada Y, Tanaka S, Kobayshi T, Tatsuguchi A, Sakamoto C. Gastrointestinal manifestations in Henoch-Schönlein purpura. Nippon Rinsho 2008; 66: 1350-6.
31. Ronkainen J, Koskimies O, Houhala MA, Antikainene M, Merenmies J, Rajante J, Örmala T, Turtinen J, Nuutinen M. Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006; 149: 241-7.
32. Peru H, Soylemezoglu O, Bakkaloglu SC, Elmas S, Bozkaya D, Elmaci AM, Kara F, Buyan N, Hasanoglu E. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008; 27:1087-1092.

Source(s) of Funding

---

none

Competing Interests

---

none

Disclaimer

---

This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party.
Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website.